Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone

Esther W. Bouman-Wammes*, John M.H. de Klerk, Haiko J. Bloemendal, Jocye M. Van Dodewaard-de Jong, Rogier Lange, Rob ter Heine, Henk M.W. Verheul, Alfons J.M. Van den Eertwegh

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review


For patients with castration-resistant prostate cancer metastatic to bone, treatment with radiopharmaceuticals is a promising but yet underutilized treatment option. In this review, we describe the effects on pain palliation and survival and the specific characteristics of the different radiopharmaceuticals as monotherapy or combined with chemotherapy.

Original languageEnglish
Pages (from-to)e281-e292
JournalClinical Genitourinary Cancer
Issue number2
Publication statusPublished - Apr 2019

Cite this